TY  - GEN
AU  - Harbeck,Nadia
AU  - Gluz,Oleg
AU  - Christgen,Matthias
AU  - Kates,Ronald Ernest
AU  - Braun,Michael
AU  - Küemmel,Sherko
AU  - Schumacher,Claudia
AU  - Potenberg,Jochem
AU  - Kraemer,Stefan
AU  - Kleine-Tebbe,Anke
AU  - Augustin,Doris
AU  - Aktas,Bahriye
AU  - Forstbauer,Helmut
AU  - Tio,Joke
AU  - von Schumann,Raquel
AU  - Liedtke,Cornelia
AU  - Grischke,Eva-Maria
AU  - Schumacher,Johannes
AU  - Wuerstlein,Rachel
AU  - Kreipe,Hans Heinrich
AU  - Nitz,Ulrike Anneliese
TI  - De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET
SN  - 1527-7755
PY  - 2017///0915
KW  - Ado-Trastuzumab Emtansine
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - therapeutic use
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - metabolism
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Female
KW  - Humans
KW  - Maytansine
KW  - analogs & derivatives
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Precision Medicine
KW  - methods
KW  - Prospective Studies
KW  - Receptor, ErbB-2
KW  - biosynthesis
KW  - Trastuzumab
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1200/JCO.2016.71.9815
ER  -